stockrowRegeneron Pharmaceuticals, Inc.
REGN Healthcare Biotechnology
Regeneron Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $14.3 billion, up 0.99% from fiscal 2024.
- Revenue
- +36.3%
- EPS
- +36.0%
- Free cash flow
- +3.85%
- Total debt
- −26.6%
Quarter to September 2026, against a year earlier
Follow REGN
Alert me
Regeneron Pharmaceuticals, Inc. (REGN) Return on equity
Regeneron Pharmaceuticals, Inc.'s return on equity over the twelve months to 30 September 2026 was 15.0%, up 0.1 percentage points from fiscal 2025 (14.9%). Over the past ten years it has ranged from 14.9% (fiscal 2025) to 54.2% (fiscal 2021) — the current reading is the lowest in ten years. That is above the Biotechnology industry median of −50.1% and above the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 14.9% | (1.08) |
| FY2024 | 16.0% | (0.31) |
| FY2023 | 16.3% | (4.68) |
| FY2022 | 20.9% | (33.27) |
| FY2021 | 54.2% | 22.44 |
| FY2020 | 31.8% | 10.45 |
| FY2019 | 21.3% | (11.49) |
| FY2018 | 32.8% | 10.18 |
| FY2017 | 22.6% | 0.53 |
| FY2016 | 22.1% | 1.60 |
Against its own ten years
Return on equity against peers
| Company | Return on equity |
|---|---|
| VRTX Vertex Pharmaceuticals Incorporated compare | 20.8% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 18.4% |
| REGN Regeneron Pharmaceuticals, Inc. | 15.0% |
| GMAB Genmab A/S Sponsored ADR compare | 14.0% |
| ARGX argenex SE compare | 0.00% |
| RPRX Royalty Pharma PLC compare | 0.00% |
| ROIV Roivant Sciences Ltd. compare | −5.47% |
| MRNA Moderna, Inc. compare | −39.0% |
| RVMD Revolution Medicines, Inc. compare | −93.6% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on REGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement